Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Biogen Inc. provided a mixed set of results in its first quarter of 2025, revealing both opportunities for its growing portfolio and challenges with its traditional business lines.</li><li>Starting with the positives, the company has made significant strides with its newer products, contrasting its historically dominant but declining multiple sclerosis (MS) portfolio.</li><li>The newer products, including rare disease drugs like ZURZUVAE, LEQEMBI, and VUMERITY, now account for approximately 45% of Biogen’s product revenue.</li></ul>

Biogen Inc. provided a mixed set of results in its first quarter of 2025, revealing both opportunities for its growing portfolio and challenges with its traditional business lines.Starting with the positives, the company has made significant strides with its newer products, contrasting its historically dominant but declining multiple sclerosis (MS) portfolio.The newer products, including rare disease drugs like ZURZUVAE, LEQEMBI, and VUMERITY, now account for approximately 45% of Biogen’s product revenue.

Biogen Inc.: The Game-Changing Subcutaneous LEQEMBI Might Just Be Its Single-Biggest Future Growth Catalyst!

<ul><li>Biogen Inc.'s fourth-quarter and full-year 2024 financial results highlight a company in transition, balancing the challenges of competition in its core multiple sclerosis (MS) franchise while seeking growth avenues through new product launches and pipeline prioritization.</li><li>Biogen's earnings call detailed their strategic focus on launching innovative treatments, optimizing their pipeline, and reshaping company operations to align with future growth opportunities.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Biogen Inc.'s fourth-quarter and full-year 2024 financial results highlight a company in transition, balancing the challenges of competition in its core multiple sclerosis (MS) franchise while seeking growth avenues through new product launches and pipeline prioritization.Biogen's earnings call detailed their strategic focus on launching innovative treatments, optimizing their pipeline, and reshaping company operations to align with future growth opportunities.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Biogen Inc.: Expansion into Immunology & Rare Diseases Is Key Diversification Strategy But Will It Work?

<ul><li>Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic objectives.</li><li>This dual focus underscores Biogen’s efforts in addressing existing market demands while steering through the inherent complexities of pharmaceutical development and market penetration.</li><li>Starting on a positive note, Biogen reported several advancements in key areas.</li></ul>

Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic objectives.This dual focus underscores Biogen’s efforts in addressing existing market demands while steering through the inherent complexities of pharmaceutical development and market penetration.Starting on a positive note, Biogen reported several advancements in key areas.

Biogen Inc.: Market Expansion & Commercial Execution Of New Launches Driving Our 'Buy' Rating! - Major Drivers

<ul><li>Biogen recently reported its earnings for the second quarter of 2024.</li><li>The company, a leading biotechnology entity known for its pioneering work in neuroscience, highlighted a period of transformative growth and strategic reshuffling under President and CEO Chris Viehbacher.</li><li>Central to the earnings discussion was Biogen's emphasis on accelerating new product launches, optimizing existing portfolios, and expanding through strategic acquisitions, notably the addition of HI-Bio.</li></ul>

Biogen recently reported its earnings for the second quarter of 2024.The company, a leading biotechnology entity known for its pioneering work in neuroscience, highlighted a period of transformative growth and strategic reshuffling under President and CEO Chris Viehbacher.Central to the earnings discussion was Biogen's emphasis on accelerating new product launches, optimizing existing portfolios, and expanding through strategic acquisitions, notably the addition of HI-Bio.

Biogen Inc.: How Is Their Expansion and Execution of New Product Launches Going? - Major Drivers

US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mongodb-inc" target="_blank" data-smartkarma-citation="entities:26655:1" rel="noopener">MongoDB (MDB US)</a> is forecasted to be deleted from Nasdaq100 on 16 May due to an index weighting of lower than 0.1% on the last day of March and April.</li>
<li>
<a href="https://www.smartkarma.com/entities/shopify-inc-de74469e-4678-489b-9b50-a80a5790c5ef" target="_blank" data-smartkarma-citation="entities:25906:1" rel="noopener">Shopify (SHOP US)</a> is the forecasted replacement. The company became eligible following its listing transfer from NYSE to Nasdaq on 31 March.</li>
<li>
<a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a> and <a href="https://www.smartkarma.com/entities/ebay-inc" target="_blank" data-smartkarma-citation="entities:1291:1" rel="noopener">eBay Inc (EBAY US)</a> are the main addition candidates for the acquisition of <a href="https://www.smartkarma.com/entities/ansys-inc" target="_blank" data-smartkarma-citation="entities:15473:1" rel="noopener">Ansys Inc (ANSS US)</a> by mid-2025 and the December 2025 review.</li>
</ul>



MongoDB (MDB US) is forecasted to be deleted from Nasdaq100 on 16 May due to an index weighting of lower than 0.1% on the last day of March and April.

Shopify (SHOP US) is the forecasted replacement. The company became eligible following its listing transfer from NYSE to Nasdaq on 31 March.

Alnylam Pharmaceuticals (ALNY US) and eBay Inc (EBAY US) are the main addition candidates for the acquisition of Ansys Inc (ANSS US) by mid-2025 and the December 2025 review.


MongoDB (MDB US): Fast-Exit from Nasdaq100 in May 2025

United States

Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biogen Inc (BIIB US)

Biogen Inc.: The Game-Changing Subcutaneous LEQEMBI Might Just Be Its Single-Biggest Future Growth Catalyst!

Biogen Inc. provided a mixed set of results in its first quarter of 2025, revealing both opportunities for its growing portfolio and challenges...

Baptista Research

Biogen Inc.: Expansion into Immunology & Rare Diseases Is Key Diversification Strategy But Will It Work?

Biogen Inc.'s fourth-quarter and full-year 2024 financial results highlight a company in transition, balancing the challenges of competition in...

Baptista Research

Biogen Inc.: Market Expansion & Commercial Execution Of New Launches Driving Our 'Buy' Rating! - Major Drivers

Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic...

Baptista Research

Biogen Inc.: How Is Their Expansion and Execution of New Product Launches Going? - Major Drivers

Biogen recently reported its earnings for the second quarter of 2024. The company, a leading biotechnology entity known for its pioneering work in...

Baptista Research

MongoDB (MDB US): Fast-Exit from Nasdaq100 in May 2025

MDB is set to be removed from Nasdaq100 on 16 May due to its low index weighting, with SHOP expected to replace it. ALNY and EBAY are potential...

Dimitris Ioannidis

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)